Updated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre-treated multiple myeloma

71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up data to be submitted to regulatory authorities, with biologics license application on track to be submitted to the fda this year regeneron to host virtual investor event to discuss results alongside updates across its hematology portfolio on thursday, december 14 at 8:30 a.m. et tarrytown, n.y.
REGN Ratings Summary
REGN Quant Ranking